Review ArticleClinical Review

Management of Patients With Venous Thromboembolism After the Initial Treatment Period

Timothy M. Fernandes, Manreet Kanwar and Richard White
The Journal of the American Board of Family Medicine March 2021, 34 (2) 409-419; DOI: https://doi.org/10.3122/jabfm.2021.02.200085

References

  1. 1.↵
    1. Heit JA
    . Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005;3:1611–717.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Klok FA,
    2. Dzikowska-Diduch O,
    3. Kostrubiec M,
    4. et al
    . Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost 2016;14:121–8.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Lang IM,
    2. Madani M
    . Update on chronic thromboembolic pulmonary hypertension. Circulation 2014;130:508–18.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Owens GM,
    2. Fine C,
    3. Harrington DW,
    4. et al
    . Improving transitions of care for patients with thromboembolic disease. Am J Manag Care 2014;20:S81–S91. (suppl).
    OpenUrl
  5. 5.↵
    1. Jaffray J,
    2. Rajpurkar M,
    3. Sharathkumar A,
    4. et al
    . Transition of care for patients with venous thromboembolism: rationale, design and implementation of a quality intervention project conducted at American Thrombosis and Hemostasis Network (ATHN) affiliated sites. Thromb Res 2018;163:146–52.
    OpenUrl
  6. 6.↵
    1. Dobesh PP,
    2. Ahuja T,
    3. Davis GA,
    4. et al
    . Best practices for implementing venous thromboembolism prophylaxis across the continuum of care. Am J Manag Care 2018;24:S483–S488.
    OpenUrl
  7. 7.↵
    1. Kearon C,
    2. Akl EA,
    3. Ornelas J,
    4. et al
    . Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report [published correction appears in. Chest. 2016;150(4):988]. Chest 2016;149:315–52.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. den Exter PL,
    2. van Es J,
    3. Kroft LJ
    , Prometheus Follow-Up Investigators, et al. Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism. Thromb Haemost 2015;114:26–34.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Alonso-Martinez JL,
    2. Anniccherico-Sanchez FJ,
    3. Urbieta-Echezarreta MA,
    4. Garcia-Sanchotena JL,
    5. Herrero HG
    . Residual pulmonary thromboemboli after acute pulmonary embolism. Eur J Intern Med 2012;23:379–83.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Klok FA,
    2. Tijmensen JE,
    3. Haeck ML,
    4. van Kralingen KW,
    5. Huisman MV
    . Persistent dyspnea complaints at long-term follow-up after an episode of acute pulmonary embolism: results of a questionnaire. Eur J Intern Med 2008;19:625–9.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Kahn SR,
    2. Hirsch AM,
    3. Akaberi A,
    4. et al
    . Functional and exercise limitations after a first episode of pulmonary embolism: results of the ELOPE prospective cohort study. Chest 2017;151:1058–68.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Sanchez O,
    2. Helley D,
    3. Couchon S,
    4. et al
    . Perfusion defects after pulmonary embolism: risk factors and clinical significance. J Thromb Haemost 2010;8:1248–55.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Pesavento R,
    2. Filippi I,
    3. Palla A,
    4. et al
    . Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism. Eur Respir J 2017;49:1601980.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Gall H,
    2. Hoeper MM,
    3. Richter MJ,
    4. Cacheris W,
    5. Hinzmann B,
    6. Mayer E
    . An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA. Eur Respir Rev 2017;26:160121.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Ende-Verhaar YM,
    2. Cannegieter SC,
    3. Vonk Noordegraaf A,
    4. et al
    . Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J 2017;49:1601792.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Konstantinides SV,
    2. Torbicki A,
    3. Agnelli G,
    4. et al
    . ESC guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014;35:3033–69, 2014.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Galie N,
    2. Humbert M,
    3. Vachiery JL,
    4. et al
    . ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2015;37:67–119, 2016.
    OpenUrlPubMed
  18. 18.↵
    1. Konstantinides SV,
    2. Meyer G,
    3. Becattini C
    , The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC), et al. ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019;54:1901647. 2019.
    OpenUrlFREE Full Text
  19. 19.↵
    National Quality Forum. National Voluntary Consensus Standards for Prevention and Care of Venous Thromboembolism: Policy, Preferred Practices, and Initial Performance Measures. Washington, DC: National Quality Forum; 2006. Available at www.qualityforum.org/Publications/2006/12/National_Voluntary_Consensus_Standards_for_Prevention_and_Care_of_Venous_Thromboembolism__Policy,_Preferred_Practices,_and_Initial_Performance_Measures.aspx. Accessed June 7, 2019.
  20. 20.↵
    1. Coquoz N,
    2. Weilenmann D,
    3. Stolz D,
    4. et al
    . Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism. Eur Respir J 2018;51:1702505.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Kim NH,
    2. Delcroix M,
    3. Jais X,
    4. et al
    . Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019;53:1801915.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Kim NH,
    2. Delcroix M,
    3. Jenkins DP,
    4. et al
    . Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013;62:D92–D99. (suppl).
    OpenUrlFREE Full Text
  23. 23.↵
    1. Tunariu N,
    2. Gibbs S,
    3. Win Z,
    4. et al
    . Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007;48:680–4.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Tapson VF,
    2. Platt DM,
    3. Xia F,
    4. et al
    . Monitoring for pulmonary hypertension following pulmonary embolism: the INFORM Study. Am J Med 2016;129:978–85.e2.
    OpenUrl
  25. 25.↵
    1. Sostman HD,
    2. Stein PD,
    3. Gottschalk A,
    4. Matta F,
    5. Hull R,
    6. Goodman L
    . Acute pulmonary embolism: sensitivity and specificity of ventilation-perfusion scintigraphy in PIOPED II study. Radiology 2008;246:941–6.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Held M,
    2. Grun M,
    3. Holl R,
    4. et al
    . Cardiopulmonary exercise testing to detect chronic thromboembolic pulmonary hypertension in patients with normal echocardiography. Respiration 2014;87:379–87.
    OpenUrlPubMed
  27. 27.↵
    1. Fernandes TM,
    2. Alotaibi M,
    3. Strozza D,
    4. et al
    . Dyspnea post pulmonary embolism from VD/VT and stroke volume deficits during exercise [in press]. Chest 2020;157:936–44.
    OpenUrl
  28. 28.↵
    1. Kahn SR,
    2. Galanaud JP,
    3. Vedantham S,
    4. Ginsberg JS
    . Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis 2016;41:144–53.
    OpenUrl
  29. 29.↵
    1. van Dongen CJ,
    2. Prandoni P,
    3. Frulla M,
    4. Marchiori A,
    5. Prins MH,
    6. Hutten BA
    . Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005;3:939–42.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Kahn SR,
    2. Shrier I,
    3. Julian JA,
    4. et al
    . Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008;149:698–707.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Imberti D
    . D-dimer testing: advantages and limitations in emergency medicine for managing acute venous thromboembolism. Intern Emerg Med 2007;2:70–1.
    OpenUrlPubMed
  32. 32.↵
    1. Henke PK,
    2. Comerota AJ
    . An update on etiology, prevention, and therapy of postthrombotic syndrome. J Vasc Surg 2011;53:500–9.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Kahn SR,
    2. Shrier I,
    3. Shapiro S,
    4. et al
    . Six-month exercise training program to treat post-thrombotic syndrome: a randomized controlled two-centre trial. CMAJ 2011;183:37–44.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Cohen JM,
    2. Akl EA,
    3. Kahn SR
    . Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. Chest 2012;141:308–20.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Kahn SR,
    2. Shapiro S,
    3. Wells PS
    , SOX trial investigators, et al. Compression stockings to prevent post-thrombotic syndrome: a randomized placebo-controlled trial. Lancet 2014;383:880–8.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Kearon C,
    2. Ageno W,
    3. Cannegieter SC,
    4. Cosmi B,
    5. Geersing G-J,
    6. Kyrle PA
    , for the Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016;14:1480–3.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Konstantinides S,
    2. Meyer G,
    3. Becattini C,
    4. et al
    . ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS. Eur Heart J 2019.
  38. 38.↵
    1. Prandoni P,
    2. Noventa F,
    3. Ghirarduzzi A,
    4. et al
    . The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92:199–205.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Tritschler T,
    2. Wells PS
    . Extended therapy for unprovoked venous thromboembolism: when is it indicated? Blood Adv 2019;3:499.
    OpenUrlFREE Full Text
  40. 40.↵
    1. Kearon C,
    2. Akl EA,
    3. Comerota AJ,
    4. et al
    . Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e419S–494. (suppl):eS-eS.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. McRae S,
    2. Tran H,
    3. Schulman S,
    4. Ginsberg J,
    5. Kearon C
    . Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006;368:371–8.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Rodger MA,
    2. Kahn SR,
    3. Wells PS,
    4. et al
    . Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. Can Med Assoc J 2008;179:417–26.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Rodger MA,
    2. Le Gal G,
    3. Anderson DR
    , REVERSE II Study Investigators, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ 2017;356:j1065.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. White RH,
    2. Dager WE,
    3. Zhou H,
    4. Murin S
    . Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost 2006;96:267–73.
    OpenUrlPubMed
  45. 45.↵
    1. White RH,
    2. Keenan CR
    . Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 2009;123:S11–S17. (suppl).
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Agnelli G,
    2. Buller HR,
    3. Cohen A,
    4. et al
    . AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699–708.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Weitz JI,
    2. Lensing AWA,
    3. Prins MH,
    4. et al
    . Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017;376:1211–22.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Giannini J,
    2. Wong M,
    3. Dager W,
    4. MacDonald S,
    5. White RH
    . Direct oral anticoagulants are high-risk medications with potentially complex dosing. Available at http://psnet.ahrq.gov/web-mm/direct-oral-anticoagulants-are-high-risk-medications-potentially-complex-dosing Published June 29, 2020. Accessed July 14, 2020.
  49. 49.↵
    1. Garcia D,
    2. Akl EA,
    3. Carr R,
    4. Kearon C
    . Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013;122:817–24.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. De Stefano V,
    2. Martinelli I,
    3. Mannucci PM,
    4. et al
    . The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 2001;113:630–5.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    1. Shaheen K,
    2. Alraies MC,
    3. Alraiyes AH,
    4. Christie R
    . Factor V Leiden: how great is the risk of venous thromboembolism? Cleve Clin J Med 2012;79:265–72.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Middeldorp S
    . Evidence-based approach to thrombophilia testing. J Thromb Thrombolysis 2011;31:275–81.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.↵
    1. Stevens SM,
    2. Woller SC,
    3. Bauer KA,
    4. et al
    . Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 2016;41:154–64.
    OpenUrl
  54. 54.↵
    1. Pengo V,
    2. Tripodi A,
    3. Reber G
    , Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009;7:1737–40.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    1. Flieder T,
    2. Weiser M,
    3. Eller T,
    4. et al
    . Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants. Thromb Res 2018;165:101–6.
    OpenUrl
  56. 56.↵
    1. Gardiner C,
    2. Hills J,
    3. Machin SJ,
    4. Cohen H
    . Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 2013;22:18–25.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Pengo V,
    2. Banzato A,
    3. Bison E,
    4. Zoppellaro G,
    5. Padayattil Jose S,
    6. Denas G
    . Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 2016;25:301–6.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Baumann Kreuziger LM,
    2. Datta YH,
    3. Johnson AD,
    4. Zantek ND,
    5. Shanley R,
    6. Reding MT
    . Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing. Blood Coagul Fibrinolysis 2014;25:232–6.
    OpenUrl
  59. 59.↵
    1. Perry SL,
    2. Samsa GP,
    3. Ortel TL
    . Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies. Thromb Haemost 2005;94:1196–202.
    OpenUrlPubMedWeb of Science
  60. 60.↵
    1. White RH,
    2. Brunson A,
    3. Romano PS,
    4. Li Z,
    5. Wun T
    . Outcomes after vena cava filter use in noncancer patients with acute venous thromboembolism: a population-based study. Circulation 2016;133:2018–29.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    US Food and Drug Administration. Inferior vena cava (IVC) filters: initial communication: risk of adverse events with long term use. 2010. Available at www.ecnmag.com/news/2010/08/inferior-vena-cava-ivc-filters-initial-communication-risk-adverse-events-long-term-use. Published August 9, 2010. Accessed June 2, 2020.
  62. 62.↵
    1. Husseinzadeh H,
    2. Carrier M
    . Occult cancer detection in patients with hemostatic disorder and venous thromboembolism. Thromb Res 2018;163:242–5.
    OpenUrl
  63. 63.↵
    1. White RH,
    2. Chew HK,
    3. Zhou H,
    4. et al
    . Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005;165:1782–7.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Palareti G,
    2. Cosmi B,
    3. Legnani C
    , DULCIS (D-dimer and ULtrasonography in Combination Italian Study) Investigators, et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 2014;124:196–203.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Kabrhel C,
    2. Mark Courtney D,
    3. Camargo CA Jr.,
    4. et al
    . Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med 2010;17:589–97. Jun.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    1. Hoffmann TC,
    2. Montori VM,
    3. Del Mar C
    . The connection between evidence-based medicine and shared decision making. JAMA 2014;312:1295–6.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords